HRP20201634T1 - Monoklonsko protutijelo protiv interleukina-31 - Google Patents

Monoklonsko protutijelo protiv interleukina-31 Download PDF

Info

Publication number
HRP20201634T1
HRP20201634T1 HRP20201634TT HRP20201634T HRP20201634T1 HR P20201634 T1 HRP20201634 T1 HR P20201634T1 HR P20201634T T HRP20201634T T HR P20201634TT HR P20201634 T HRP20201634 T HR P20201634T HR P20201634 T1 HRP20201634 T1 HR P20201634T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
cdr2
cdr3
acid sequence
Prior art date
Application number
HRP20201634TT
Other languages
English (en)
Inventor
Gary F. BAMMERT
Steven A. DUNHAM
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46704979&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201634(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HRP20201634T1 publication Critical patent/HRP20201634T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (16)

1. Izolirano protutijelo koje se specifično veže na mačji IL-31, naznačeno time što navedeno protutijelo smanjuje, inhibira ili neutralizira pSTAT signaliziranje posredovano mačjim IL-31 u ispitivanju na stanicama.
2. Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što je navedeno protutijelo monoklonsko protutijelo.
3. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što je protutijelo kimerno.
4. Protutijelo u skladu s patentnim zahtjevom 2, naznačeno time što je protutijelo felinizirano.
5. Izolirano protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili njegov dio koji se veže na antigen, naznačeno time što sadrži najmanje jedno iz skupine koju čine: područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog (VH) lanca s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1); CDR2 varijabilnog teškog lanca s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2); CDR3 varijabilnog teškog lanca s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i njegova varijanta koja ima jednu ili više konzervativnih zamjena aminokiselina u najmanje jednom od CDR1, CDR2 ili CDR3.
6. Izolirano protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili njegov dio koji se veže na antigen, naznačeno time što sadrži najmanje jedno iz skupine koju čine: varijabilni laki (VL) lanac koji sadrži područje za određivanje komplementarnosti (CDR)1 s aminokiselinskim slijedom RASESVDNYGISFMH (SEQ ID NO:10; 11E12-VL-CDR1) ili KASQSVSFAGTGLMH (SEQ ID NO: 12; 34D03-VL-CDR1); CDR2 varijabilnog lakog lanca s aminokiselinskim slijedom RASNLES (SEQ ID NO: 13; 11E12-VL-CDR2) ili RASNLEA (SEQ ID NO: 15; 34D03-VL-CDR2); CDR3 varijabilnog lakog lanca s aminokiselinskim slijedom QQSNKDPLT (SEQ ID NO: 16; 11E12-VL-CDR3) QQSREYPWT (SEQ ID NO: 18; 34D03-VL-CDR3); i njegova varijanta koja ima jednu ili više konzervativnih zamjena aminokiselina u najmanje jednom od CDR1, CDR2 ili CDR3.
7. Protutijelo u skladu s patentnim zahtjevom 6, naznačeno time što dodatno sadrži najmanje jedno iz skupine koju čine: područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog lanca s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1); CDR2 varijabilnog teškog lanca s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2); CDR3 varijabilnog teškog lanca s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i njegova varijanta koja ima jednu ili više konzervativnih zamjena aminokiselina u najmanje jednom od CDR1, CDR2 ili CDR3.
8. Protutijelo u skladu s patentnim zahtjevom 7, naznačeno time što sadrži najmanje jedno iz skupine koju čine: a) varijabilni laki lanac koji sadrži DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMHWYQQKPGQPPKLLIYRASNLESGIPARFSGSGSRTDFTLTINPVETDDVATYYCQQSNKDPLTFGAGTKLELK (SEQ ID NO: 19; MU-11E12-VL), DIVMTQTPLSLSVSPGEPASISCRASESVDNYGISFMHWYQQKPGQPPKLLIYRASNLESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQSNKDPLTFGAGTKLEIK (SEQ ID NO: 20; CAN-11E12-VL-cUn-FW2), DIVMTQTPLSLSVSPGEPASISCRASESVDNYGISFMHWFQQKPGQSPQLLIYRASNLESGVPDRFSGSGSGTDFTLRISRVEADDAGVYYCQQSNKDPLTFGAGTKLEIK (SEQ ID NO: 21; CAN-11E12-VL-cUn-13), DILLTQSPASLAVSLGQRAIISCKASQSVSFAGTGLMHWYQQKPGQQPKLLIYRASNLEAGVPTRFSGSGSRTDFTLNIHPVEEEDAATYFCQQSREYPWTFGGGTKLEIK (SEQ ID NO: 24; MU-34D03-VL), EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK (SEQ ID NO: 25; CAN-34D03-VL-998-1), ili EIQMTQSPSSLSASPGDRVTITCKASQSVSFAGTGLMHWYQQKPGKVPKLLIYRASNLEAGVPSRFSGSGSGTDFTLTISSLEPEDAATYYCQQSREYPWTFGQGTKLEIK (SEQ ID NO: 71; FEL-34D03-VL-021-1); b) varijabilni teški lanac koji sadrži QVQLQQSGAELVKPGASVKLSCKASGYTFKYYDINWVRQRPEQGLEWIGWIFPGDGGTKYNETFKGKATLTTDKSSSTAYMQLSRLTSEDSAVYFCARGGTSVIRDAMDYWGQGTSVTVSS (SEQ ID NO: 26; MU-11E12-VH), EVQLVQSGAEVKKPGASVKVSCKTSGYTFKYYDINWVRQAPGAGLDWMGWIFPGDGGTKYNETFKGRVTLTADTSTSTAYMELSSLRAGDIAVYYCARGGTSVIRDAMDYWGQGTLVTVSS (SEQ ID NO: 27; CAN-11E12-VH-415-1), EVQLVESGGDLVKPGGSLKLSCAASGFSFSNYGMSWVRQTPDKRLEWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMSSLKSEDTAMYYCVRGYGYDTMDYWGQGTSVTVSS (SEQ ID NO: 30; MU-34D03-VH), EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS (SEQ ID NO: 31; CAN-34D03-VH-568-1), ili DVQLVESGGDLVKPGGSLRLTCVASGFTYSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLKTEDTATYYCVRGYGYDTMDYWGQGTLVTVSS (SEQ ID NO: 73; FEL-34D03-VH-035-1) i c) njegove varijante koje imaju jednu ili više konzervativnih zamjena aminokiselina.
9. Stanica domaćin, naznačena time što proizvodi protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 8.
10. Izolirana nukleinska kiselina koja kodira protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što sadrži nukleinskokiselinski slijed koji kodira najmanje jedno iz skupine koju čine: područje za određivanje komplementarnosti (CDR)1 varijabilnog teškog (VH) lanca s aminokiselinskim slijedom YYDIN (SEQ ID NO: 1; 11E12-VH-CDR1) ili NYGMS (SEQ ID NO: 3; 34D03-VH-CDR1); CDR2 varijabilnog teškog lanca s aminokiselinskim slijedom WIFPGDGGTKYNETFKG (SEQ ID NO: 4; 11E12-VH-CDR2) ili TISYGGSYTYYPDNIKG (SEQ ID NO: 6; 34D03-VH-CDR2); CDR3 varijabilnog teškog lanca s aminokiselinskim slijedom ARGGTSVIRDAMDY (SEQ ID NO: 7; 11E12-VH-CDR3) ili VRGYGYDTMDY (SEQ ID NO: 9; 34D03-VH-CDR3); i njegova varijanta koja ima jednu ili više konzervativnih zamjena aminokiselina u najmanje jednom od CDR1, CDR2 ili CDR3, te koja dodatno sadrži nukleinskokiselinski slijed koji kodira najmanje jedno iz skupine koju čine: varijabilni laki (VL) lanac koji sadrži područje za određivanje komplementarnosti (CDR)1 s aminokiselinskim slijedom RASESVDNYGISFMH (SEQ ID NO: 10; 11E12-VL-CDR1) ili KASQSVSFAGTGLMH (SEQ ID NO: 12; 34D03-VL-CDR1); CDR2 varijabilnog lakog lanca s aminokiselinskim slijedom RASNLES (SEQ ID NO: 13; 11E12-VL-CDR2) ili RASNLEA (SEQ ID NO: 15; 34D03-VL-CDR2); CDR3 varijabilnog lakog lanca s aminokiselinskim slijedom QQSNKDPLT (SEQ ID NO: 16; 11E12-VLCDR3) ili QQSREYPWT (SEQ ID NO: 18; 34D03-VL-CDR3); i njegova varijanta koja ima jednu ili više konzervativnih zamjena aminokiselina u najmanje jednom od CDR1, CDR2 ili CDR3.
11. Vektor, naznačen time što sadrži nukleinsku kiselinu u skladu s patentnim zahtjevom 10.
12. Postupak proizvodnje protutijela, naznačen time što se sastoji u uzgoju stanice domaćina u skladu s patentnim zahtjevom 9 u uvjetima koji dovode do proizvodnje protutijela, te izoliranju protutijela iz stanice domaćina ili medija za uzgoj stanice domaćina.
13. Postupak detektiranja ili kvantificiranja IL-31 u uzorku, naznačen time što se postupak sastoji u: (a) inkubiranju kliničkog ili biološkog uzorka koji sadrži IL-31 u prisutnosti protutijela u skladu s bilo kojim od patentnih zahtjeva 1 do 8; i (b) detektiranju protutijela vezanog na IL-31 u uzorku.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time što je protutijelo obilježeno na dokazivi način.
15. Postupak u skladu s patentnim zahtjevom 13, naznačen time što protutijelo nije obilježeno i upotrebljava se u kombinaciji s drugim protutijelom koje je obilježeno na dokazivi način.
16. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što se specifično veže na područje na mačjem IL-31 koje odgovara području između aminokiselinskih ostataka 95 i 125 u aminokiselinskom slijedu SEQ ID NO: 32 psećeg IL-31.
HRP20201634TT 2011-07-21 2020-10-09 Monoklonsko protutijelo protiv interleukina-31 HRP20201634T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161510268P 2011-07-21 2011-07-21
EP17168574.6A EP3219729B1 (en) 2011-07-21 2012-07-05 Interleukin-31 monoclonal antibody

Publications (1)

Publication Number Publication Date
HRP20201634T1 true HRP20201634T1 (hr) 2020-12-25

Family

ID=46704979

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171198TT HRP20171198T1 (hr) 2011-07-21 2017-08-03 Monoklonsko protutijelo protiv psećeg interleukina-31
HRP20201634TT HRP20201634T1 (hr) 2011-07-21 2020-10-09 Monoklonsko protutijelo protiv interleukina-31

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20171198TT HRP20171198T1 (hr) 2011-07-21 2017-08-03 Monoklonsko protutijelo protiv psećeg interleukina-31

Country Status (24)

Country Link
US (6) US8790651B2 (hr)
EP (4) EP3842456A1 (hr)
JP (1) JP6022563B2 (hr)
KR (2) KR101613024B1 (hr)
CN (2) CN105504059B (hr)
AR (1) AR087281A1 (hr)
AU (2) AU2012285432C1 (hr)
BR (1) BR112014001407A8 (hr)
CA (2) CA2926379A1 (hr)
CY (2) CY1119475T1 (hr)
DK (1) DK2734549T3 (hr)
ES (2) ES2638340T3 (hr)
HR (2) HRP20171198T1 (hr)
HU (2) HUE034282T2 (hr)
LT (2) LT2734549T (hr)
ME (1) ME02837B (hr)
MX (1) MX349053B (hr)
PL (2) PL2734549T3 (hr)
PT (2) PT2734549T (hr)
RS (2) RS56268B1 (hr)
SI (2) SI2734549T1 (hr)
UY (1) UY34206A (hr)
WO (1) WO2013011407A1 (hr)
ZA (1) ZA201400768B (hr)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101329843B1 (ko) * 2002-11-15 2013-11-14 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
EP3345607B1 (en) 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
EP3248617A3 (en) * 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
HUE036548T2 (hu) 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
BR112012028920B1 (pt) * 2010-05-14 2021-03-23 Amgen Inc. Formulações líquidas estéreis de anticorpo de alta concentração e método para reduzir a viscosidade de uma formulação de proteína
RU2663123C2 (ru) * 2010-11-30 2018-08-01 Чугаи Сейяку Кабусики Кайся Индуцирующий цитотоксичность терапевтический агент
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TR201816416T4 (tr) 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Risperidona yönelik antikorlar ve bunların kullanımı.
CA2882490A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
EP3590537A1 (en) * 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
US9499621B2 (en) * 2013-04-08 2016-11-22 Cytodyn, Inc. Felinized antibodies and methods of treating retroviral infections in felines
CA2918795A1 (en) * 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
AU2014346770B2 (en) * 2013-11-06 2020-05-21 Janssen Biotech, Inc. Anti-CCL17 antibodies
US11072647B2 (en) * 2013-12-19 2021-07-27 Onsejo Nacional DE Investigation Cientiticay Tecnica TGF-receptor II isoform, fusion peptide, methods of treatment and methods in vitro
CA2932515C (en) * 2013-12-20 2023-08-01 Intervet International B.V. Caninized antibodies
ES2923641T3 (es) * 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
WO2015120138A2 (en) * 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
EP3102599B1 (en) * 2014-02-06 2019-02-27 ARSANIS Biosciences GmbH E. coli specific antibody sequences
HRP20231514T1 (hr) 2014-03-26 2024-03-01 Julius-Maximilians-Universität Würzburg Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka
WO2015196142A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN106999577B (zh) * 2014-07-16 2021-12-21 特兰斯吉恩股份有限公司 溶瘤病毒和免疫检查点调节因子组合
WO2016075612A1 (en) * 2014-11-12 2016-05-19 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
WO2016104657A1 (ja) * 2014-12-26 2016-06-30 橋本 正 癌治療剤
BR112017015661A2 (pt) 2015-01-30 2018-03-20 Saitama Medical University anticorpo anti-alk2
CN107921104A (zh) * 2015-02-22 2018-04-17 索伦托治疗有限公司 结合cd137的抗体疗法
BR112017020955A2 (pt) * 2015-03-31 2018-07-10 Medimmune Limited forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
KR102514173B1 (ko) * 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
US11424061B2 (en) * 2015-04-14 2022-08-23 Hanchett Entry Systems, Inc. Solenoid assembly actuation using resonant frequency current controller circuit
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
BR112018009064A8 (pt) * 2015-11-17 2019-02-26 Jiangsu Hengrui Medicine Co anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
US20190023786A1 (en) * 2016-01-12 2019-01-24 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
BR112018071965A2 (pt) * 2016-04-27 2019-03-06 Benchmark Animal Health Ltd tratamento da dermatite atópica canina
CN107474134B (zh) * 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102492057B1 (ko) * 2016-06-15 2023-01-26 노파르티스 아게 골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
CN110035769A (zh) * 2016-09-21 2019-07-19 奈斯科尔公司 针对siglec-15的抗体及其使用方法
CA3043365A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
BR112019012731A2 (pt) * 2016-12-21 2019-11-26 Mereo Biopharma 3 Ltd uso de anticorpos antiesclerostina no tratamento de osteogênese imperfeita
US11680101B2 (en) * 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
EP3582813A4 (en) * 2017-02-16 2020-12-30 XBiotech, Inc TREATMENT OF SUPPURATIVE HIDRADENITIS
WO2018156250A1 (en) * 2017-02-21 2018-08-30 Remd Biotherapeutics, Inc. Cancer treatment using antibodies that bind cytotoxic t-lymphocyte antigen-4 (ctla-4)
WO2018156367A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
JP7314115B2 (ja) * 2017-03-31 2023-07-25 セレクティス ソシエテ アノニム ユニバーサル抗ｃｄ２２キメラ抗原受容体操作免疫細胞
EP3609922A2 (en) * 2017-04-13 2020-02-19 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3630824A1 (en) * 2017-05-26 2020-04-08 GlaxoSmithKline Intellectual Property Development Ltd Biopharmaceutical compositions and related methods
WO2018219327A1 (zh) * 2017-06-01 2018-12-06 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
TWI726228B (zh) * 2017-08-09 2021-05-01 國立臺灣大學 Ｃｄ１４拮抗分子用於治療癌症
SG11201913969SA (en) * 2017-08-16 2020-01-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16, and egfr, hla-e ccr4, or pd-l1
JP7226833B2 (ja) * 2017-09-21 2023-02-21 イムチェック セラピューティクス エスエーエス Ｂｔｎ２に特異性を有する抗体及びその使用
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
WO2019086694A1 (en) 2017-11-06 2019-05-09 Geert Mudde Il31 antigen and vaccine
WO2019104157A1 (en) * 2017-11-21 2019-05-31 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
KR20210009296A (ko) * 2017-12-11 2021-01-26 유비아이 아이피 홀딩스 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물
MA51289A (fr) 2017-12-18 2021-03-24 Regeneron Pharma Molécules de liaison à l'antigène bispécifiques se liant au récepteur de la leptine et/ou à gp130, et leurs procédés d'utilisation
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
AU2019218136A1 (en) 2018-02-08 2020-08-13 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
EP3749353A1 (en) * 2018-02-09 2020-12-16 Nestlé Skin Health SA Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
AU2019236328A1 (en) 2018-03-16 2020-09-10 Zoetis Services Llc Peptide vaccines against Interleukin-31
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
EP3770262A4 (en) * 2018-03-16 2021-12-15 National University Corporation Shiga University of Medical Science ANTIBODY FRAGMENT DEGRADING AND ELIMINATING ABNORMAL TDP-43
US11608381B2 (en) * 2018-04-06 2023-03-21 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
WO2019216675A1 (ko) * 2018-05-09 2019-11-14 주식회사 굳티셀 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
EP3806885A2 (en) * 2018-06-13 2021-04-21 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
TWI822815B (zh) * 2018-07-14 2023-11-21 財團法人生物技術開發中心 抗-人類ｐｄ-ｌ１之抗體及其用途
TWI803682B (zh) * 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗－ｇｄｆ１５抗體、組成物及使用方法
US20220267428A1 (en) * 2018-10-10 2022-08-25 The Board Of Trustees Of The Leland Stanford Junior University BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
CA3120474A1 (en) * 2018-12-21 2020-06-25 23Andme, Inc. Anti-il-36 antibodies and methods of use thereof
MA54657A (fr) * 2019-01-03 2021-11-10 Invetx Inc Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation
AU2020240132A1 (en) * 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
EP3947441A1 (en) * 2019-03-27 2022-02-09 UMC Utrecht Holding B.V. Engineered iga antibodies and methods of use
EP3962936A1 (en) * 2019-05-03 2022-03-09 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
CN110283246A (zh) * 2019-06-20 2019-09-27 长春西诺生物科技有限公司 一种抗猫细小病毒的猫源化基因工程抗体
US11890353B2 (en) * 2019-10-15 2024-02-06 Northwestern University Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
BR112022006590A2 (pt) * 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos
EP4077380A1 (en) 2019-12-20 2022-10-26 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
CA3162031A1 (en) 2019-12-20 2021-06-24 Mohamad Morsey Canine interleukin-4 receptor alpha antibodies
WO2021207242A2 (en) * 2020-04-07 2021-10-14 Fred Hutchinson Cancer Research Center Anti-mesothelin antigen-binding molecules and uses thereof
US20230242635A1 (en) 2020-04-17 2023-08-03 Zoetis Services Llc Canine antibody variants
JP2023522030A (ja) * 2020-04-17 2023-05-26 ゾエティス・サービシーズ・エルエルシー ネコ科動物抗体バリアント
BR112022021450A2 (pt) * 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
TWI800824B (zh) * 2020-05-08 2023-05-01 大陸商亘喜生物科技（上海）有限公司 一種抗cd19抗體的抗體及其製備和應用
US11434276B2 (en) 2020-05-11 2022-09-06 Invetx, Inc. Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
IL298257A (en) * 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
WO2022010652A1 (en) 2020-07-10 2022-01-13 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in felines and methods of use
MX2023001490A (es) * 2020-08-05 2023-04-27 Synthekine Inc Moleculas de union a il27r\03b1 y metodos de uso.
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
AU2021327387A1 (en) * 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
FR3113458B1 (fr) 2020-08-21 2022-10-14 Purally Composition comprenant au moins un flavonoide glycosyle et son utilisation en cosmetique ou dermatologie
IL301413A (en) 2020-09-28 2023-05-01 Zoetis Services Llc Canine antibody variants
PE20240110A1 (es) 2020-09-29 2024-01-22 Zoetis Services Llc Variantes de anticuerpos felinos
WO2022079139A1 (en) * 2020-10-15 2022-04-21 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
TW202221039A (zh) 2020-10-19 2022-06-01 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
WO2022094009A1 (en) * 2020-10-30 2022-05-05 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies to sars-cov-2 nucleocapsid protein
EP4247848A1 (en) * 2020-11-23 2023-09-27 Scout Bio, Inc. Antigen-binding molecules and uses thereof
EP4263596A1 (en) * 2020-12-18 2023-10-25 Zoetis Services LLC Mutations in feline antibody constant regions
KR20230136604A (ko) 2021-01-28 2023-09-26 조에티스 서비시즈 엘엘씨 개과 항체 불변 영역에서의 돌연변이
EP4284830A1 (en) 2021-01-29 2023-12-06 Bayer Animal Health GmbH Vaccine composition for breaking self-tolerance
AU2022223713A1 (en) 2021-02-22 2023-09-07 Zoetis Services Llc Horse il-31 induced pruritus model
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
US20220348659A1 (en) * 2021-03-24 2022-11-03 Twist Bioscience Corporation Variant nucleic acid libraries for cd3
AU2022260544A1 (en) * 2021-04-23 2023-11-30 Astrazeneca Ab Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab
CA3227725A1 (en) 2021-08-20 2023-02-23 Mohamad Morsey Homodimer fusion proteins for treating atopic dermatitis
WO2023111128A1 (en) 2021-12-16 2023-06-22 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha ii
WO2023152486A1 (en) 2022-02-09 2023-08-17 Petmedix Ltd Therapeutic antibodies
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2024057096A1 (en) 2022-09-14 2024-03-21 Ceva Sante Animale Treatment of atopic dermatitis using self-replicating rna expressing il-31
CN115505575B (zh) * 2022-11-16 2023-03-24 中国科学院天津工业生物技术研究所 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350576A (en) 1991-09-13 1994-09-27 Mycogen Corporation Bacillus thuringiensis isolates for controlling acarides
US6194167B1 (en) 1997-02-18 2001-02-27 Washington State University Research Foundation ω-3 fatty acid desaturase
WO1999061618A2 (en) * 1998-05-29 1999-12-02 Heska Corporation Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
EP1161530B1 (en) 1999-03-18 2005-05-18 MERCK PATENT GmbH Protein for blocking platelet adhesion
US6790639B2 (en) 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
CN100455599C (zh) * 2000-03-03 2009-01-28 协和发酵工业株式会社 基因重组抗体及其抗体片段
KR100419555B1 (ko) 2000-05-29 2004-02-19 주식회사유한양행 비형간염바이러스의 에스-표면항원을 인식하는단일클론항체의 가변영역 및 이를 코딩하는 유전자
US6818444B2 (en) * 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
EP1485126A4 (en) * 2001-12-21 2007-03-21 Idexx Lab Inc DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE
CN100575482C (zh) 2002-01-18 2009-12-30 津莫吉尼蒂克斯公司 新的细胞因子zcytor17配体
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
KR20060015602A (ko) * 2003-05-31 2006-02-17 마이크로메트 에이지 ＥｐＣＡＭ 에 대한 이중 특이성 항체를 포함하는약학조성물
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
ES2579758T3 (es) 2005-01-28 2016-08-16 Zymogenetics, Inc. Preparaciones homogéneas de IL-31
WO2006088955A2 (en) 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
US20060182743A1 (en) 2005-02-14 2006-08-17 Janine Bilsborough Methods of treating skin disorders using an IL-31RA antagonist
JP2008535823A (ja) * 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
CN101198624B (zh) 2005-05-06 2012-10-10 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
AU2007249713A1 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using IL-31Ra and OSMRb antagonists
JP5230022B2 (ja) * 2006-08-09 2013-07-10 ベイラー リサーチ インスティテュート 抗インターフェロンアルファモノクローナル抗体及び使用方法
EP2759549B1 (en) 2006-09-01 2015-08-19 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
JP5238710B2 (ja) 2006-10-19 2013-07-17 シーエスエル、リミテッド インターロイキン−１３レセプターアルファ１の高親和性抗体アンタゴニスト
HUE036548T2 (hu) 2007-12-07 2018-08-28 Zymogenetics Inc IL-31-re specifikus humanizált antitest molekulák
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
EP2331579B1 (en) 2008-09-04 2017-07-05 Vet Therapeutics, Inc. Monoclonal antibodies
WO2011065935A1 (en) 2009-11-24 2011-06-03 Cornell University Methods for monoclonal antibody production
WO2010117448A2 (en) * 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
MX2012004415A (es) 2009-10-15 2012-05-08 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
KR20220017432A (ko) 2010-02-24 2022-02-11 이뮤노젠 아이엔씨 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
EP2644698B1 (en) 2010-11-17 2018-01-03 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013014105A1 (en) 2011-07-22 2013-01-31 Glaxosmithkline Biologicals S.A. Prame purification
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use

Also Published As

Publication number Publication date
PL3219729T3 (pl) 2021-01-25
SI3219729T1 (sl) 2020-11-30
ZA201400768B (en) 2015-12-23
CN105504059B (zh) 2020-08-11
CA2842475C (en) 2018-01-02
US10421807B2 (en) 2019-09-24
CN105504059A (zh) 2016-04-20
KR101613024B1 (ko) 2016-04-18
LT3219729T (lt) 2020-11-25
HUE051068T2 (hu) 2021-01-28
US8790651B2 (en) 2014-07-29
RS60924B1 (sr) 2020-11-30
CY1119475T1 (el) 2018-03-07
US20190359702A1 (en) 2019-11-28
US20140315251A1 (en) 2014-10-23
MX349053B (es) 2017-07-06
US20140286958A1 (en) 2014-09-25
ES2638340T3 (es) 2017-10-19
CN103890009B (zh) 2017-02-15
AU2012285432A1 (en) 2014-01-30
PT2734549T (pt) 2017-08-29
JP6022563B2 (ja) 2016-11-09
UY34206A (es) 2013-02-28
NZ620031A (en) 2016-03-31
AU2016203590B2 (en) 2017-12-21
WO2013011407A1 (en) 2013-01-24
EP2734549B1 (en) 2017-05-24
HUE034282T2 (en) 2018-02-28
HRP20171198T1 (hr) 2017-10-20
KR20160028488A (ko) 2016-03-11
RU2014101250A (ru) 2015-08-27
US20190389944A1 (en) 2019-12-26
EP3842456A1 (en) 2021-06-30
PT3219729T (pt) 2020-10-23
US10526405B2 (en) 2020-01-07
US20130022616A1 (en) 2013-01-24
BR112014001407A8 (pt) 2022-11-08
BR112014001407A2 (pt) 2017-03-01
RS56268B1 (sr) 2017-11-30
CA2926379A1 (en) 2013-01-24
AU2016203590A1 (en) 2016-06-16
EP3219729B1 (en) 2020-09-09
EP3653645A1 (en) 2020-05-20
AU2012285432B2 (en) 2016-06-16
ME02837B (me) 2018-01-20
US20190092854A1 (en) 2019-03-28
AU2012285432C1 (en) 2016-12-22
EP2734549A1 (en) 2014-05-28
ES2827231T3 (es) 2021-05-20
JP2014529295A (ja) 2014-11-06
CN103890009A (zh) 2014-06-25
SI2734549T1 (sl) 2017-10-30
KR101742928B1 (ko) 2017-06-01
LT2734549T (lt) 2017-09-11
KR20140041858A (ko) 2014-04-04
PL2734549T3 (pl) 2017-11-30
EP3219729A1 (en) 2017-09-20
AR087281A1 (es) 2014-03-12
US9206253B2 (en) 2015-12-08
MX2014000803A (es) 2014-03-31
CY1123791T1 (el) 2022-03-24
CA2842475A1 (en) 2013-01-24
DK2734549T3 (en) 2017-09-11

Similar Documents

Publication Publication Date Title
HRP20201634T1 (hr) Monoklonsko protutijelo protiv interleukina-31
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
HRP20160461T1 (hr) Solubilna humana st-2 antitijela i eseji
KR20230016184A (ko) 코로나바이러스에 대한 변이체 핵산 라이브러리
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
HRP20150623T1 (hr) Monoklonalno protutijelo sposobno za vezivanje na specifiäśni diskontinuirani epitop koji se pojavljuje u podruäśju ad1 od humanog glikoproteina citomegalovirusa gb, te njegov fragment koji se veže na antigen
IL275270A (en) Recombinant scavenger cell surface proteins
JP2013506428A5 (hr)
JP2020504101A5 (hr)
JP2018535670A5 (hr)
JP2013535191A5 (hr)
HRP20171067T1 (hr) Terapeutska upotreba specifičnih liganda u bolestima povezanim sa msrv
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
RU2010133547A (ru) Анти-cldn антитела
JP2008538289A5 (hr)
HRP20130877T1 (hr) Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
PE20160553A1 (es) Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
JP2016516400A5 (hr)
JP2015529202A5 (hr)
HRP20211541T1 (hr) Anti-asic1 antitijela i njihove upotrebe
HRP20161459T1 (hr) Protutijela koja se specifično vežu na receptor epidermnog čimbenika rasta
JP2010513228A5 (hr)
Adler et al. Rare, high-affinity mouse anti-PD-1 antibodies that function in checkpoint blockade, discovered using microfluidics and molecular genomics
JP2018527895A5 (hr)
RU2013105487A (ru) Антитела против нейропилина и способы их применения